Viking Therapeutics, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; filed March 21, 2017. Although the request identifies 2016 Q4, this 10-K reports full-year results, and the filing text does not provide a clear standalone fourth-quarter financial summary.
Business context
Viking is a clinical-stage biopharmaceutical company developing metabolic and endocrine therapies. It had no product revenue and depended on external financing. Its principal programs were VK5211 (Phase 2, hip-fracture rehabilitation) and VK2809 (Phase 2, hypercholesterolemia and fatty liver disease); VK0214 was preclinical for X-linked adrenoleukodystrophy (X-ALD). VK0612 was described as Phase 2b-ready for type 2 diabetes, with additional preclinical anemia and metabolic programs. The portfolio is licensed from Ligand Pharmaceuticals.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.00 million | $6.97 million |
| General and administrative expense | $4.85 million | $5.03 million |
| Total operating expenses | $13.85 million | $12.00 million |
| Net loss | $14.73 million | $23.40 million |
| Basic and diluted loss per share | $0.90 | $3.68 |
| Cash used in operating activities | $11.07 million | $8.73 million |
| Cash and cash equivalents at year-end | $3.08 million | $0.77 million |
| Short-term investments at year-end | $10.08 million | $13.34 million |
R&D expense rose 29.2%, mainly due to clinical-trial and preclinical activity, partly offset by lower manufacturing and stock-compensation expense. G&A declined 3.6%. Net loss narrowed substantially, primarily because FY2015 included a $9.38 million non-cash charge from remeasuring accrued Ligand license fees; FY2016 other expense was $0.88 million versus $11.41 million in FY2015. As a pre-revenue company, operating or gross margins are not meaningful.
At December 31, 2016, cash plus short-term investments totaled approximately $13.15 million. Current assets were $13.97 million and current liabilities $6.48 million. Total liabilities were $6.49 million; the balance sheet reported $3.27 million of current convertible notes payable, net of discount, and a $0.73 million current debt-conversion-feature liability. Financing activities provided $10.35 million; investing activities provided $3.03 million, primarily reflecting investment maturities and purchases.
The independent auditor and management identified substantial doubt about the company’s ability to continue as a going concern: management did not expect available resources to fund operations for 12 months after issuance without additional capital. The financial statements contain no adjustments for the outcome of that uncertainty.
Material changes and financing
- FY2016 net loss improved from FY2015, but operating cash use increased by $2.34 million.
- The April 2016 offering generated approximately $9.04 million net proceeds, including over-allotment proceeds; the company also issued warrants exercisable at $1.50 per share. It repaid $1.5 million of Ligand debt, with $300,000 paid in cash and $1.2 million settled using shares and a warrant.
- The company sold shares through its Maxim equity distribution agreement and Aspire Capital arrangement during 2016. After year-end, it reported additional net proceeds of $2.54 million from those arrangements and $1.8 million from a February 2017 sale to PoC Capital earmarked for certain clinical trials.
- Potential dilution is material: 9.67 million common-stock warrants were outstanding at year-end, in addition to options and shares issuable in connection with Ligand debt. Common shares outstanding were 20.82 million at year-end and 23.83 million as of February 28, 2017.
Outlook, commentary and risks
- Management expected to complete the VK5211 Phase 2 hip-fracture trial in mid-2017 and the approximately 80-patient VK2809 Phase 2 trial in the second half of 2017. These were expectations, not reported outcomes.
- Following preliminary positive findings in a GSD Ia animal model, Viking planned further proof-of-concept work and, if positive, an IND filing for VK2809 in the second half of 2017. VK0214 animal-model work was ongoing, with IND-enabling work contingent on results.
- Early clinical findings were preliminary: VK5211 Phase 1 studies reported lean-mass gains and no drug-related serious adverse events; VK2809 Phase 1 reported LDL-C and triglyceride reductions, but also mild liver-enzyme increases at higher doses and dose-related thyroid-hormone shifts. These results do not establish efficacy or safety in larger trials.
- The company had no manufacturing facilities and relied on third parties for clinical supply. It also relied substantially on Ligand’s licensed technology; the license includes royalties and potential development, regulatory and sales milestones of up to approximately $1.54 billion in aggregate.
- The Ligand note was secured by company assets and included restrictive covenants and potentially significant repayment terms. If the note is not repaid by maturity and Ligand demands repayment, the agreement describes a repayment amount equal to 200% of outstanding principal and accrued unpaid interest.
- Key risks include clinical and regulatory failure or delay, enrollment and supply constraints, need for further financing and resulting dilution, competition, dependence on Ligand and contract manufacturers, patent protection, and uncertain reimbursement. No material legal proceedings were reported. Management said disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Current cash runway and subsequent financing needs, including actual proceeds and share issuance under the Maxim, Aspire and PoC arrangements.
- Results and timing of the VK5211 and VK2809 Phase 2 trials, and whether the conditional GSD Ia and VK0214 development plans advanced.
- Remaining Ligand debt, maturity and repayment provisions, license milestones and royalties, and any effect of Ligand’s ownership or governance rights.
- Fully diluted share count and potential warrant, option and debt-related dilution.
- Whether the company can maintain adequate clinical supplies and patent protection, and whether preliminary safety and efficacy observations are confirmed in larger studies.